IL-33 in Chronic Respiratory Disease: From Preclinical to Clinical Studies

IL-33 in Chronic Respiratory Disease: From Preclinical to Clinical Studies.

Full text not available from this repository.
Item Type: Review
Status: Published
Official URL: https://doi.org/10.1021/acsptsci.9b00099
Journal or Publication Title: ACS Pharmacology & Translational Science
Volume: 3
Number: 1
Page Range: pp. 56-62
Date: 2020
Divisions: UTS Centre for Inflammation
Depositing User: General Admin
Identification Number: 10.1021/acsptsci.9b00099
ISSN: 2575-9108
Date Deposited: 25 Mar 2021 03:56
Abstract:

IL-33 has been deorphanized as a member of the IL-1 family and has key roles as an alarmin and cytokine with potent capacity to drive type 2 inflammation. This has led to a plethora of studies surrounding its role in chronic diseases with a type 2 inflammatory component. Here, we review the roles of IL-33 in two chronic respiratory diseases, asthma and chronic obstructive pulmonary disease (COPD). We discuss the hallmark and paradigm-shifting studies that have contributed to our understanding of IL-33 biology. We cover animal studies that have elucidated the mechanisms of IL-33 and assessed the role of anti-IL-33 treatment and immunization against IL-33. We highlight key clinical evidence for the potential of targeting increased IL-33 in respiratory diseases including exacerbations, and we outline current clinical trials using an anti-IL-33 monoclonal antibody in asthma patients. Finally, we discuss some of the challenges that have arisen in IL-33 biology and highlight potential future directions in targeting this cytokine in chronic respiratory diseases.

Copyright © 2019 American Chemical Society.

Creators:
Creators
Email
Donovan, Chantal
UNSPECIFIED
Hansbro, Philip M.
UNSPECIFIED
Last Modified: 25 Mar 2021 03:56
URI: https://eprints.centenary.org.au/id/eprint/963

Actions (login required)

View Item View Item